Nevro Corp. is focused on the development and commercialization of HF-SCS for the treatment of chronic pain and other disorders. The company has developed the Senza HF-SCS system, the only SCS system capable of providing HF10TM SCS therapy by delivering stimulation of up to 10kHz. The company's proprietary high-frequency technology appears unique in its potential to effectively treat challenging conditions such as low back pain while enhancing patient experience.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/07/13 | $48,000,000 | Series C |
Accuitive Medical Ventures Johnson & Johnson Innovation Mayo Clinic MPM Capital Novo Ventures | undisclosed |
